Signaling lymphocytic activation molecule and Nectin cell adhesion molecule 4 (SLAM (CD150) and Nectin-4 (PVRL4))

Signaling lymphocytic activation molecule (SLAM, CD150) is an immunoglobulin superfamily cell surface receptor expressed primarily on activated lymphocytes and antigen-presenting cells. It regulates immune responses and serves as a cellular entry point for the measles virus in immune cells. Nectin cell adhesion molecule 4 (Nectin-4, PVRL4) is a type I transmembrane protein of the immunoglobulin superfamily, predominantly expressed in embryonic and placental tissues, and at low levels in several adult epithelial tissues. It plays key roles in cell-cell adhesion, organization of adherens and tight junctions, regulation of angiogenesis, epithelial-mesenchymal transition, and tumor progression. Nectin-4 also acts as a high-affinity epithelial cell receptor for measles virus and is upregulated in various cancers, making it an important target for antibody-drug conjugate therapy (such as enfortumab vedotin). Note: For structured information, SLAM and Nectin-4 should be handled as separate canonical targets, as they are distinct molecules.

Other names

CD150SLAMF1Nectin-4PVRL4

SLAM: Viral inhibition (by blocking measles virus entry via receptor binding). Nectin-4: Antibody-drug conjugate binds Nectin-4 on cancer cells, delivering cytotoxic payload (enfortumab vedotin mechanism).